Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network

The Abramson Cancer Center (ACC) at the University of Pennsylvania announced today that it is joining the National Comprehensive Cancer Network (NCCN) as its 28th member institution.

20 Nov 2018

New first-line treatment for peripheral T-cell lymphoma approved by FDA

The U.S. Food and Drug Administration today expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

16 Nov 2018

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

Person's sex hormones may play key role in trauma survival, finds study

A person's sex hormones may play a role in trauma survival, according to a Kansas State University researcher who has received a $650,000 grant from the U.S. Department of Defense.

16 Nov 2018

Anopheles species may be important vectors driving spread of Mayaro virus in the U.S.

Mosquitoes of the genus Anopheles are well known as primary vectors of malaria. But a new study suggests that Anopheles species, including some found in the United States, also are capable of carrying and transmitting an emerging pathogen, Mayaro virus, which has caused outbreaks of disease in South America and the Caribbean.

9 Nov 2018

Advances in radiation treatment help prolong, improve lives of people with anal cancer

Two recent studies find advances in radiation therapy are helping to prolong or improve the lives of people with anal cancer, including those whose cancer has advanced to stage IV.

8 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Researchers for first time view serotonin activating its receptor using high-powered microscopes

Serotonin receptors are common drug targets in the treatment of pain, gastrointestinal dysfunctions, and mood disorders yet little is known about their three-dimensional structure.

2 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Scientists working hard to better understand endometriosis

About 10 percent of women worldwide suffer from endometriosis, a painful and debilitating disease with inadequate treatments.

1 Nov 2018

Scientists describe novel conjugates made from antibodies and protein inhibitor

Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects--especially when treating tumors. In the journal Angewandte Chemie, scientists have now described novel conjugates made from antibodies and a kinesin spindle protein inhibitor.

31 Oct 2018

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment.

29 Oct 2018

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Stroke specialists often see conditions known as stroke "mimics" and "chameleons" that can complicate accurate diagnoses, Loyola Medicine neurologists report in the November 2018 issue of Neuroimaging Clinics of North America.

26 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

Scientists discover primary, direct target of alcohol in the brain

When alcohol enters the brain, it causes neurons in a specialized region called the ventral tegmental area, or VTA -- also known as the "pleasure center" -- to release dopamine, a neurotransmitter that produces those feel-good sensations, and tells the brain that whatever it just experienced is worth getting more of.

23 Oct 2018

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or "chemo brain," symptoms and unwanted side effects of opioids.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Nausea News and Research

Further Reading

Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network

New first-line treatment for peripheral T-cell lymphoma approved by FDA

Nexus announces availability of Arsenic Trioxide Injection in the US

Person's sex hormones may play key role in trauma survival, finds study

Anopheles species may be important vectors driving spread of Mayaro virus in the U.S.

Advances in radiation treatment help prolong, improve lives of people with anal cancer

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Researchers for first time view serotonin activating its receptor using high-powered microscopes

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Scientists working hard to better understand endometriosis

Scientists describe novel conjugates made from antibodies and protein inhibitor

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Scientists discover primary, direct target of alcohol in the brain

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

Study: Targeting specific genomic mutation in breast cancer improves survival

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News